From a bulk purchasing perspective, tirzepatide is currently more readily available than retatrutide through both pharmaceutical and research channels, since tirzepatide already has FDA approval (as Mounjaro for type 2 diabetes and Zepbound for weight management)
As of February 2026, Lilly plans to submit for orforglipron for type 2 diabetes sometime in 2026
Ships in 2448 business hours
doi: 10.5888/pcd19.220347 3 SunHSaeediPKarurangaSPinkepankMOgurtsovaKDuncanBBet al
Understanding FDA labeling guidance, your lifestyle factors, and how timing affects side effects will help you and your healthcare provider determine the optimal schedule for your GLP-1 therapy
Chronic hyperglycemia in diabetes downregulates GIP receptor (GIPR) expression and impairs GIP-mediated insulin secretion [21], rendering high-doses of GIP infusions ineffective [22]